Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Cardiac Energy Metabolism in Barth Syndrome
EF 2018-19
Résumé
Heart failure presents as the leading cause of infant death in patients with Barth Syndrome, a rare genetic disorder first described by Peter Barth and colleagues in 1983. Fortunately, with current medical strategies, individuals with Barth Syndrome now have a greater likelihood of surviving past infancy, however heart disease remains a constant clinical concern throughout their lifespan. Recently, it has been discovered that the heart of an individual with Barth Syndrome may not be able to produce energy as efficiently as a healthy heart. Because of this malfunction in energy production, the heart is compromised in its ability to effectively pump blood through the rest of the body, thus leading to heart failure. The goal of our research is to determine whether correcting the heart’s ability to produce energy may be an effective therapy to prevent the development of heart disease in Barth Syndrome. Our early data has suggested that the Barth Syndrome heart may be impaired in its ability to effectively burn sugar for energy, and that an energy source made by the liver, the ketone body, may be a better substrate for the Barth Syndrome heart to metabolize. Recently, a genetically modified mouse model has been developed with the same genetic mutation that causes Barth syndrome, and these mice also develop heart failure mimicking the human condition. We will treat these mice with drugs that increase sugar (dichloroacetate) or ketone body (empagliflozin) metabolism in the heart, and assess whether these drugs improve heart function and prevent heart failure. If our hypothesis is correct, our research will suggest that increasing the heart’s ability to burn sugar and/or ketone bodies for energy, may be an exciting approach to prevent heart failure in Barth Syndrome children.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406285
Name
Greenwell Amanda A
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Cardiac Energy Metabolism in Barth Syndrome
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Barth Syndrome; Cardiomyopathy; Energy Metabolism; Heart Failure
Abstract
Heart failure presents as the leading cause of infant death in patients with Barth Syndrome, a rare genetic disorder first described by Peter Barth and colleagues in 1983. Fortunately, with current medical strategies, individuals with Barth Syndrome now have a greater likelihood of surviving past infancy, however heart disease remains a constant clinical concern throughout their lifespan. Recently, it has been discovered that the heart of an individual with Barth Syndrome may not be able to produce energy as efficiently as a healthy heart. Because of this malfunction in energy production, the heart is compromised in its ability to effectively pump blood through the rest of the body, thus leading to heart failure. The goal of our research is to determine whether correcting the heart’s ability to produce energy may be an effective therapy to prevent the development of heart disease in Barth Syndrome. Our early data has suggested that the Barth Syndrome heart may be impaired in its ability to effectively burn sugar for energy, and that an energy source made by the liver, the ketone body, may be a better substrate for the Barth Syndrome heart to metabolize. Recently, a genetically modified mouse model has been developed with the same genetic mutation that causes Barth syndrome, and these mice also develop heart failure mimicking the human condition. We will treat these mice with drugs that increase sugar (dichloroacetate) or ketone body (empagliflozin) metabolism in the heart, and assess whether these drugs improve heart function and prevent heart failure. If our hypothesis is correct, our research will suggest that increasing the heart’s ability to burn sugar and/or ketone bodies for energy, may be an exciting approach to prevent heart failure in Barth Syndrome children.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Greenwell, Amanda A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~